The Cancer Letter

Inside information on cancer research and drug development

Funding Opportunities

ALK Positive, LUNGevity Foundation issue RFA for lung cancer research award program

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print
BYLINE
IN THIS ISSUE
DOWNLOAD PDFTABLE OF CONTENTS

ALK Positive and LUNGevity Foundation have issued a Request for Application for ALK-positive Lung Cancer Research Awards to be granted in 2022. 

Letters of intent are due by Feb. 23, 2022. For those invited to submit a full application, the due date will be May 9, 2022.

Funded projects are expected to have a direct impact on the outcomes of patients with advanced ALK-positive lung cancer, but innovative proposals that address other unmet needs in the ALK-positive lung cancer space are also invited for submission. 

The ALK-positive award has no geographical restrictions; international researchers may apply. The successful applicant may receive up to $750,000 over an award term of two years.

The Request for Applications is posted on the proposalCENTRAL website here. For more information, contact Margery Jacobson at mjacobson@LUNGevity.org.

Table of Contents

YOU MAY BE INTERESTED IN

In Brief

MD Anderson’s Lauren Averett Byers receives TAMEST O’Donnell Award

Lauren Averett Byers, professor of thoracic/head & neck medical oncology at the University of Texas MD Anderson Cancer Center, received the 2025 Edith and Peter O’Donnell Award in Medicine from the Texas Academy of Medicine, Engineering, Science and Technology. The award recognizes her fundamental discoveries and contributions to identifying novel therapeutic strategies for small cell lung cancer, which have paved the way for personalized treatments, even in the most highly recalcitrant cancers.
In Brief

Break Through Cancer launches the PoweRD 2 Cure ALK+ Lung Cancer TeamLab

Break Through Cancer has launched the PoweRD 2 Cure ALK+ Lung Cancer TeamLab, a collaboration among nine leading cancer research institutions, including Break Through Cancer’s five partner institutions: Dana-Farber Cancer Institute, Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Memorial Sloan Kettering Cancer Center, MIT’s Koch Institute for Integrative Cancer Research, and the University of Texas MD Anderson Cancer Center, as well as newly engaged collaborators from Mass General Brigham, Boston Children’s Hospital, the University of Colorado Cancer Center and Vanderbilt University Medical Center.
Clinical Roundup

Tecentriq + tiragolumab does not improve OS, updated phase III data finds

Genentech’s phase III SKYSCRAPER-01 study, evaluating tiragolumab combined with Tecentriq (atezolizumab) compared to Tecentriq alone for patients with PD-L1-high, locally advanced or metastatic non-small cell lung cancer, did not reach the primary endpoint of overall survival at the final analysis. The overall safety profile observed remained consistent with longer follow-up, and no new safety signals were identified. The detailed data will be presented at a medical meeting in 2025.
Table of Contents

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login

Site license subscribers:
Log in with your IP | Register a sponsored account